Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours.
Although IAPP was first discovered and isolated from amyloid deposits in an endocrine pancreatic tumour (EPT), surprisingly few reports have investigated the potential use of IAPP as a marker for neuroendocrine tumour growth. In this study we present results from plasma measurements of IAPP in 102 patients with neuroendocrine tumours. Four of 35 patients (11%) with midgut carcinoid tumours, but none of the patients (4 and 5, respectively) with lung carcinoids or with rectal carcinoids displayed elevated plasma levels of IAPP. Five of 31 patients (16%) with sporadic EPT and 3 of 27 patients (11%) with EPT and multiple endocrine neoplasia type 1 syndrome disclosed elevated IAPP levels. Within the different syndromes, 1/11 individuals with insulinoma, 2/16 with gastrinoma, 0/2 with glucagonoma, 0/3 with VIPoma and 5/26 with non-functioning tumours showed elevated plasma levels of IAPP. In two patients, the plasma IAPP levels were extremely elevated. These patients also exhibited altered glucose homeostasis. In response to a standardised mixed meal test, IAPP increased in parallel to the insulin, pancreatic polypeptide, gastrin and glucose responses. In MEN1 patients with hypercalcaemia due to increased secretion of parathyroid hormone, the plasma levels of IAPP were significantly higher before than after surgical removal of the parathyroid adenomas. However in normocalcaemic patients, no correlation between the blood calcium and plasma IAPP levels was found. Immunocytochemical staining of tumour tissue showed that 9/13 (69%) of insulin producing tumours, 4/14 (29%) of non-functioning tumours and 1/9 (11%) of gastrin producing tumours were IAPP immunoreactive. Amyloid deposits were always IAPP immunoreactive. In conclusion, increased circulating levels of IAPP occurred in 12% of 102 patients with neuroendocrine tumours. In 2 patients with extremely elevated plasma levels of IAPP, effects on glucose homeostasis were recorded. Thus, IAPP may be useful as an additional marker for neuroendocrine tumour growth in selected cases.
Stridsberg
M
M
Department of Clinical Chemistry, University Hospital of Uppsala, Sweden.
Eriksson
B
B
Lundqvist
G
G
Skogseid
B
B
Wilander
E
E
Oberg
K
K
D000328:Adult; D000682:Amyloid / Q000097:blood*; D001786:Blood Glucose / Q000378:metabolism; D002276:Carcinoid Tumor / Q000097:blood* / Q000175:diagnosis; D004701:Endocrine Gland Neoplasms / Q000097:blood* / Q000175:diagnosis; D005260:Female; D015408:Gastrinoma / Q000097:blood / Q000473:pathology; D005935:Glucagonoma / Q000097:blood / Q000473:pathology; D006706:Homeostasis; D006801:Humans; D007150:Immunohistochemistry; D007340:Insulinoma / Q000097:blood / Q000473:pathology; D007414:Intestinal Neoplasms / Q000097:blood / Q000175:diagnosis; D058228:Islet Amyloid Polypeptide; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D018761:Multiple Endocrine Neoplasia Type 1 / Q000097:blood / Q000175:diagnosis; D018358:Neuroendocrine Tumors / Q000097:blood* / Q000175:diagnosis; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000175:diagnosis; D011863:Radioimmunoassay; D012016:Reference Values
D000682:Amyloid; D001786:Blood Glucose; D058228:Islet Amyloid Polypeptide